/
BLTE
$153.72-$0.94 (-0.60%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.0B
40M shares
52-week range
$56.10 – $200.00
68% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$143.13
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $3.7M | $7.4M | $8.9M | $24.8M | $29.9M | $45.4M |
| Operating income | −$5.7M | −$9.8M | −$12.8M | −$31.7M | −$40.0M | −$84.2M |
| EBITDA | −$5.7M | −$9.6M | −$12.4M | −$31.2M | −$35.7M | −$77.1M |
| Net income | −$5.8M | −$9.7M | −$12.6M | −$31.6M | −$36.1M | −$77.6M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.62 | -0.40 | -0.63 | -1.19 | -1.18 | -2.31 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $23M | $-3.28 | $-3.93–$-2.87 | 6 |
| 2027 | $243M | $0.95 | $-1.75–$4.59 | 5 |
| 2028 | $573M | $7.16 | $2.02–$16.86 | 4 |
| 2029 | $1.2B | $16.28 | $6.83–$29.48 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$10.53
Price
$153.72
Implied downside
-93%
Peer comparison
Belite Bio, Inc American Depositary Shares
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
www.belitebio.com- Employees
- 41
- IPO / List date
- Apr 29, 2022
Held by traders on TradeandTell
No one on the platform currently holds BLTE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 52,000 | $8.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BLTE yet.
